GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine targets leftover disease after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
Triple-Drug attack on Hard-to-Treat stomach cancer shows promise in early trial
Disease control Recruiting nowThis Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New strategy: removing tumors one by one after chemo for stomach and pancreatic cancers
Disease control Recruiting nowThis phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cocktail of drugs could shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to halt stomach cancer spread
Disease control Recruiting nowThis study tests whether adding a drug called zanidatamab to the usual chemotherapy can slow or stop the growth of advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-positive. About 168 adults who have already tried one standard treatment will be random…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental virus and CAR t combo takes on Hard-to-Treat GI cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Dispatch Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for stomach cancer: experimental drug combo trial opens
Disease control Recruiting nowThis study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced stomach cancer: experimental drug combos enter human trials
Disease control Recruiting nowThis study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Tailored chemo shows promise for stomach cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether adjusting chemotherapy based on how a patient's tumor responds can improve outcomes for people with stomach or gastroesophageal junction cancer. About 20 participants with stage IB to III disease will receive standard chemo combinations (…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo aims to stall advanced stomach cancer
Disease control Recruiting nowThis study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. The goal is to see if the combination can keep the cancer from growing for at least 6 mo…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug BDC-4182 targets stomach cancer by waking up the immune system
Disease control Recruiting nowThis early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy targets hard-to-treat GI cancers
Disease control Recruiting nowThis early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Genetic cheat code may unlock safer, stronger chemo cocktail for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Glowing dye could help surgeons spot hidden cancers during surgery
Diagnosis Recruiting nowThis study tests whether a dye called pafolacianine (CYTALUX™) can make cancer cells glow under near-infrared light during surgery. Fifteen adults with gastric, esophageal, or appendiceal cancer will receive the dye before standard surgery. Surgeons will use a special camera to l…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jun 26, 2026 17:19 UTC